SFOSF - BioNTech Fosun Pharma COVID-19 shot cleared by expert panel in China: Caixing

Thomas Lohnes/Getty Images News The Chinese drug regulators have concluded a review of the COVID-19 vaccine co-developed by BioNTech (BNTX) and Fosun Pharma (SFOSF), reports Caixinglobal. The vaccine will be named Comirnaty, and it now heads to the review stage, Fosun, which is set to manufacture the vaccine, has said. The production is expected to get underway by the end of August, Fosun Chairman Wu Yifang said Wednesday at a shareholders meeting. Chinese authorities plan to use the vaccine, as a booster shot for people who have received COVID-19 vaccines based on inactivated viruses, Caixing reported citing people close to regulators. Previously, the head of the American Chamber of Commerce in Shanghai Ker Gibbs said the messenger-RNA-based vaccine would be greenlighted in China by June. In April, Fosun Pharma announced a joint venture with BioNTech, aiming to produce 1B doses of the vaccine.

For further details see:

BioNTech, Fosun Pharma COVID-19 shot cleared by expert panel in China: Caixing